摘要
糖尿病肾病(DN)是糖尿病(DM)常见而严重的并发症之一,其病理特征为肾小球基底膜增厚、系膜内玻璃样物质增生、内皮细胞损伤与激活。DN患者肾脏局部纤溶酶原激活物抑制物-1(PAI-1)表达增多,抑制了肾小球和肾小管间质细胞外基质(ECM)的降解,导致ECM进行性堆积,肾小球基底膜增厚,肾小球硬化。DM并发微血管病变尤其是DN时,血浆血栓调节蛋白(PTM)水平显著升高。内皮损伤伴随DN的整个发展过程,它的出现甚至早于DN微量白蛋白尿的出现。测定PAI-1、TM水平对早期诊断、早期治疗DN有重要临床意义。
Diabetic Nephropathy（DN） is one of the most common and serious complications of Diabetes meilitus（DM）, of which the pathologic character is the thickening of glomerular basement membranes, prolifieation of intramerabrane vitrina and endothelioeyte injury or activation. Enhanced the expression of plasroinogen activator inhibitor-1 （PAl-1）in kidney of DN will inhibite the degradation of ECM of interstitial cell of glomcrulus and renal tubule which will then result in progressive accumulation of ECM, thickening of gloroerulat basement membrane and glo. merulax sclerosis. When the patients with DM having eomplication of mieroangiopathy, especially DN, the level of thrombeomodulin is very high. Because endothelial dysfunction accompanied the whole process of DN, it can be found before the occurrence of trace albeminuria. Monitoring the level of PAI-1 and TM have great significance in the early diagnosis and therapy of DN.
出处
《医学综述》
2006年第6期374-376,共3页
Medical Recapitulate
